| Dr Thomas Richard Walters, MD | |
|
5717 Balcones Dr, Austin, TX 78731 | |
| (512) 327-7000 | |
| (512) 314-1662 |
| Full Name | Dr Thomas Richard Walters |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 42 Years |
| Location | 5717 Balcones Dr, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609852664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | G3889 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texan Eye, Pa | 2466440458 | 16 |
News Archive
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).
During a meeting in Atlanta on Wednesday, a "federal advisory committee issued sweeping guidelines … for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations," CNN reports (Hellerman, 7/29).
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 1 days ago
| Entity Name | Texan Eye, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205813961 PECOS PAC ID: 2466440458 Enrollment ID: O20040506000650 |
News Archive
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).
During a meeting in Atlanta on Wednesday, a "federal advisory committee issued sweeping guidelines … for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations," CNN reports (Hellerman, 7/29).
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Richard Walters, MD 5717 Balcones Dr, Austin, TX 78731-4203 Ph: (512) 327-7000 | Dr Thomas Richard Walters, MD 5717 Balcones Dr, Austin, TX 78731 Ph: (512) 327-7000 |
News Archive
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.
Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).
During a meeting in Atlanta on Wednesday, a "federal advisory committee issued sweeping guidelines … for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations," CNN reports (Hellerman, 7/29).
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 1 days ago
Dr. Kristen Michelle Hawthorne, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Saradha Chexal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy Ste 460, Austin, TX 78705 Phone: 512-454-5851 | |
Dr. John David Fisher, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2901 Montopolis Dr, Austin, TX 78741 Phone: 512-389-6571 Fax: 512-389-6511 | |
Dr. Clio Armitage Harper Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 W 38th St, Suite 200, Austin, TX 78705 Phone: 512-451-0103 Fax: 512-451-2741 | |
Dr. Nadja Ivette Torres, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Fuad Makkouk, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9707 Anderson Mill Rd Ste 230, Austin, TX 78750 Phone: 512-693-9363 | |
Irina Volosko, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3410 Far West Blvd Ste 140, Austin, TX 78731 Phone: 512-427-1107 Fax: 512-427-1207 |